Guneet Kaur Jasuja

Guneet Kaur Jasuja

Auto-generated profile, based on publicly available information

Guneet Kaur Jasuja

Center for Healthcare Organization and Implementation Research, VA Bedford Health Care System, Bedford, MA USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Medical Care
Verified
Journal Article
Closed access
GJGuneet K. Jasuja
Guneet K. Jasuja
AGAlexander de Groot
Alexander de Groot
EQEmily K. Ma Quinn
Emily K. Ma Quinn
OAOmid MD Ameli
Omid MD Ameli
JHJaclyn M.W. Hughto
Jaclyn M.W. Hughto
ARAdam J. Md Rose
Adam J. Md Rose
Background: Large administrative databases often do not capture gender identity data, limiting researchers’ ability to identify transgender people and complicating the study of this population. Objective: The objective of this study was to develop methods for identifying transgender people in a large, national dataset for insured adults. Research Design: This was a retrospective analysis of administrative claims data. After using gender identity disorder (GID) diagnoses codes, the current method for identifying transgender people in administrative data, we used the following 2 strategies to improve the accuracy of identifying transgender people that involved: (1) Endocrine Disorder Not Otherwise Specified (Endo NOS) codes and a transgender-related procedure code; or (2) Receipt of sex hormones not associated with the sex recorded in the patient’s chart (sex-discordant hormone therapy) and an Endo NOS code or transgender-related procedure code. Subjects: Seventy-four million adults 18 years and above enrolled at some point in commercial or Medicare Advantage plans from 2006 through 2017. Results: We identified 27,227 unique transgender people overall; 18,785 (69%) were identified using GID codes alone. Using Endo NOS with a transgender-related procedure code, and sex-discordant hormone therapy with either Endo NOS or transgender-related procedure code, we added 4391 (16%) and 4051 (15%) transgender people, respectively. Of the 27,227 transgender people in our cohort, 8694 (32%) were transmasculine, 3959 (15%) were transfeminine, and 14,574 (54%) could not be classified. Conclusion: In the absence of gender identity data, additional data elements beyond GID codes improves the identification of transgender people in large, administrative claims databases.

1 September 2015 in Medical Care
Verified
Journal Article
Closed access
GJGuneet K. Jasuja
Guneet K. Jasuja
SBShalender Mbbs Bhasin
Shalender Mbbs Bhasin
JRJoel I. Reisman
Joel I. Reisman
DBDan R. Berlowitz
Dan R. Berlowitz
Adam RoseAdam Rose
Adam Rose
Background: Prescribing of exogenous testosterone is increasing. Because of the risks associated with testosterone, it is important to follow evidence-based procedures when initiating therapy. Objective: We evaluated whether dispensing of testosterone was preceded by appropriate ascertainment of androgen deficiency, and consideration of potential contraindications, in accordance with practice guidelines. Research Design: A cross-sectional study. Setting: All outpatient clinics within Veterans Affairs (VA) during fiscal years 2009–2012 (FY09–FY12). Subjects: A total of 111,631 men who had not previously received testosterone from VA, and received at least 1 testosterone dispensing during the study period. A 1-year “look-back” period was used to check for diagnostic tests that occurred before the first fill. Measures: Proportion who underwent appropriate diagnostic evaluation of androgen deficiency and ascertainment of contraindications for testosterone therapy during the year before receiving their first testosterone dispensing. Results: New testosterone dispensing in VA increased from 20,437 in FY09 to 36,394 in FY12. Only 3.1% of men who received testosterone had 2 or more low (total or free) testosterone levels in the morning, LH and/or FSH level measured, and no contraindications to testosterone therapy. A total of 16.5% did not have their testosterone level checked at all. Among those prescribed therapy, 1.4% had prostate cancer, 7.6% had obstructive sleep apnea, and 3.5% had elevated hematocrit at baseline. Conclusions: Only a small proportion of men receiving testosterone in VA underwent appropriate testing, and some received this therapy despite important contraindications. Promoting a more uniform application of clinical guidelines may facilitate appropriate use of testosterone.

19 December 2016 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
GJGuneet K. Jasuja
Guneet K. Jasuja
SBShalender Bhasin
Shalender Bhasin
JRJoel I. Reisman
Joel I. Reisman
JHJoseph T. Hanlon
Joseph T. Hanlon
DMDonald R. Miller
Donald R. Miller
Adam RoseAdam Rose
Adam Rose

2 December 2019 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
GJGuneet K. Jasuja
Guneet K. Jasuja
OAOmid Ameli
Omid Ameli
JRJoel I. Reisman
Joel I. Reisman
ARAdam J. Rose
Adam J. Rose
DMDonald R. Miller
Donald R. Miller
SBShalender Bhasin
Shalender Bhasin
Opioid use in the United States has reached epidemic proportions.1 Although deaths from opioid overdose2,3 have captured the world’s attention, the endocrine complications of chronic opioid use have remained underappreciated. All opioid medications, especially long-acting opioids, suppress testosterone levels, often into the severely hypogonadal range.4,5 Prescription opioid use has been shown to have an association with testosterone deficiency; nearly 20% of testosterone prescriptions written in the Veterans Health Administration (VHA) system were for men who were opioid users.6 Testosterone deficiency among opioid users is associated with increased risk of sexual dysfunction, osteoporosis, and bone fractures.7 However, to our knowledge, no data exist on major health outcomes in opioid users who are hypogonadal and either receive or do not receive testosterone treatment.

1 March 2023 in LGBT Health
Verified
Journal Article
Closed access
GJGuneet K. Jasuja
Guneet K. Jasuja
JRJoel I. Reisman
Joel I. Reisman
SRSowmya R. Rao
Sowmya R. Rao
HWHill L. Wolfe
Hill L. Wolfe
JHJaclyn M.W. Hughto
Jaclyn M.W. Hughto
JSJillian C. Shipherd
Jillian C. Shipherd
Purpose: Health disparities in transgender and gender diverse (TGD) veterans compared with cisgender veterans have been documented. However, there is a paucity of literature focused on older TGD veterans. We assessed health conditions and social stressors in older TGD veterans compared with matched cisgender veterans. Methods: Using gender identity disorder diagnosis codes, we identified 1244 TGD veterans (65+ years of age) receiving care in the Veterans Health Administration (VHA) from 2006 to 2018. These TGD veterans were then matched to 3732 cisgender veterans based on age, VHA site, and date of care in VHA. Results: In adjusted models, TGD veterans compared with cisgender veterans were less likely to have alcohol use disorder (adjusted odds ratio [AOR; 95% confidence interval]: [0.70; 0.58–0.85]), drug use disorder (0.59; 0.47–0.74), tobacco use (0.75; 0.65–0.86), and anxiety (0.74; 0.62–0.90). However, compared with cisgender veterans, TGD veterans were more likely to experience depression (1.63; 1.39–1.93), Alzheimer's disease (8.95; 4.25–18.83), cancer (1.83; 1.56–2.14), violence (1.82; 1.14–2.91), social/familial problems (2.45; 1.99–3.02), lack of access to care/transportation (2.23; 1.48–3.37), and military sexual trauma (2.59; 1.93–3.46). Furthermore, compared with cisgender veterans, TGD veterans were more likely to have documentation of a higher count of social stressors: 1 or more stressors (1.64; 1.38–1.95) and 2 or more stressors (1.22; 1.01–1.49). Conclusion: Despite significant disparities in social stressors and health conditions compared with cisgender veterans, TGD veterans had a lower likelihood of substance use and anxiety. Interventions are needed to mitigate social stressors and improve health among the older TGD veteran population.

11 March 2021 in Medical Care
Verified
Journal Article
Closed access
GJGuneet K. Jasuja
Guneet K. Jasuja
ABAmy Bettano
Amy Bettano
DSDavid PsyD Smelson
David PsyD Smelson
DBDana Bernson
Dana Bernson
ARAdam J. Md Rose
Adam J. Md Rose
DMDonald R. ScD Miller
Donald R. ScD Miller
Background: Compared with non-Veterans, Veterans are at higher risk of experiencing homelessness, which is associated with opioid overdose. Objective: To understand how homelessness and Veteran status are related to risks of nonfatal and fatal opioid overdose in Massachusetts. Design: A cross-sectional study. Participants: All residents aged 18 years and older during 2011–2015 in the Massachusetts Department of Public Health’s Data Warehouse (Veterans: n=144,263; non-Veterans: n=6,112,340). A total of 40,036 individuals had a record of homelessness, including 1307 Veterans and 38,729 non-Veterans. Main Measures: The main independent variables were homelessness and Veteran status. Outcomes included nonfatal and fatal opioid overdose. Results: A higher proportion of Veterans with a record of homelessness were older than 45 years (77% vs. 48%), male (80% vs. 62%), or receiving high-dose opioid therapy (23% vs. 15%) compared with non-Veterans. The rates of nonfatal and fatal opioid overdose in Massachusetts were 85 and 16 per 100,000 residents, respectively. Among individuals with a record of homelessness, these rates increased 31-fold to 2609 and 19-fold to 300 per 100,000 residents. Homelessness and Veteran status were independently associated with higher odds of nonfatal and fatal opioid overdose. There was a significant interaction between homelessness and Veteran status in their effects on risk of fatal overdose. Conclusions: Both homelessness and Veteran status were associated with a higher risk of fatal opioid overdoses. An understanding of health care utilization patterns can help identify treatment access points to improve patient safety among vulnerable individuals both in the Veteran population and among those experiencing homelessness.